Last reviewed 2026-04-23 · How we verify

Anti-IL6

IL-6 receptor antagonist

IL-6 receptor antagonist Used for Rheumatoid arthritis, Multiple myeloma.

At a glance

Mechanism of action

Anti-IL6 drugs work by binding to the IL-6 receptor, preventing IL-6 from interacting with its receptor and thereby reducing inflammation.

Approved indications

• Rheumatoid arthritis
• Multiple myeloma

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia

Key clinical trials

• Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma (PHASE2)
• Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction (PHASE3)
• Pro- and Anti-inflammatory Cytokines in PCOS
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (PHASE2)
• Identify a Specific Immune Profile in Patients With Chronic Pelvic Pain Resistant to First-line Treatments by Measuring Th1, Th2, Th17, and Treg Cytokines Produced After Non-specific Functional Cell Stimulation - ImmunoCPP (NA)
• A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP (PHASE2)
• Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma (PHASE1)
• Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Anti-IL6 CI brief — competitive landscape report
• Anti-IL6 updates RSS · CI watch RSS
• Marie Hudson, MD portfolio CI